Ligand Pharmaceuticals Acquires XOMA Royalty in a $739 Million Deal
Ligand Pharmaceuticals Incorporated (LGND) entered a merger agreement on April 27, 2026, to acquire XOMA Royalty Corporation (XOMA) in a deal valued at $739 million. Deal…
Written byAsif SuriaSource: InsideArbitrage
Ligand Pharmaceuticals Incorporated (LGND) entered a merger agreement on April 27, 2026, to acquire XOMA Royalty Corporation (XOMA) in a deal valued at $739 million. Deal Structure: XOMA Royalty stockholders will receive $39 per share in cash, representing a premium of 2.9% from the stock’s last close. The stockholders will also receive one non-transferable contingent